285 related articles for article (PubMed ID: 16702617)
21. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Toscano C; Klein K; Blievernicht J; Schaeffeler E; Saussele T; Raimundo S; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):755-66. PubMed ID: 17001295
[TBL] [Abstract][Full Text] [Related]
22. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.
Llerena A; Dorado P; Peñas-Lledó EM; Cáceres MC; De la Rubia A
Pharmacogenomics J; 2007 Dec; 7(6):408-10. PubMed ID: 17325735
[TBL] [Abstract][Full Text] [Related]
23. [Genetic polymorphism of CYP-1A1, CYP2D6 and risks of chronic benzene poisoning].
Gu SY; Zhang ZB; Cao DZ; Wan JX; Gao XL; Jin XP; Xia ZL
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 May; 24(5):266-9. PubMed ID: 16737584
[TBL] [Abstract][Full Text] [Related]
24. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
25. Dystonic reactions with metoclopramide: is there a risk population?
Boulloche J; Mallet E; Mouterde O; Tron P
Helv Paediatr Acta; 1987 Jun; 42(5-6):425-32. PubMed ID: 3454349
[TBL] [Abstract][Full Text] [Related]
26. Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters.
Parkman HP; Mishra A; Jacobs M; Pathikonda M; Sachdeva P; Gaughan J; Krynetskiy E
J Clin Gastroenterol; 2012 Jul; 46(6):494-503. PubMed ID: 22688145
[TBL] [Abstract][Full Text] [Related]
27. Metoclopramide induced dystonia in children: two case reports.
Yis U; Ozdemir D; Duman M; Unal N
Eur J Emerg Med; 2005 Jun; 12(3):117-9. PubMed ID: 15891443
[TBL] [Abstract][Full Text] [Related]
28. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
29. Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?
Vandel P; Haffen E; Vandel S; Bonin B; Sechter D; Bizouard P; Dalery J
Therapie; 2000; 55(3):349-53. PubMed ID: 10967711
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.
Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C; Kolesar J
Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
[TBL] [Abstract][Full Text] [Related]
32. [Acute dyskinetic syndrome during chloropromazine treatment of a female patient with CYP2D6 poor metabolism phenotype].
Beszłej JA; Grzesiak M; Milejski P
Psychiatr Pol; 2007; 41(4):495-501. PubMed ID: 18046980
[TBL] [Abstract][Full Text] [Related]
33. Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer.
Lemos MC; Carrilho F; Rodrigues F; Coutinho E; Gomes L; Carvalheiro M; Regateiro FJ
Clin Endocrinol (Oxf); 2007 Aug; 67(2):180-3. PubMed ID: 17547692
[TBL] [Abstract][Full Text] [Related]
34. Persistent extrapyramidal syndrome with dystonia and rigidity caused by combined metoclopramide and prochlorperazine therapy.
Factor SA; Matthews MK
South Med J; 1991 May; 84(5):626-8. PubMed ID: 2035085
[TBL] [Abstract][Full Text] [Related]
35. Frequency of mutated allele CYP2D6*4 in the Turkish population.
Koseler A; Ilcol YO; Ulus IH
Pharmacology; 2007; 79(4):203-6. PubMed ID: 17374963
[TBL] [Abstract][Full Text] [Related]
36. Adverse neurologic effects of metoclopramide.
Grimes JD; Hassan MN; Preston DN
Can Med Assoc J; 1982 Jan; 126(1):23-5. PubMed ID: 7059869
[TBL] [Abstract][Full Text] [Related]
37. [Acute dystonic reactions after administration of neuroleptics and other drugs].
Prusiński A; Rózniecki J; Durko A; Głuszcz-Zielińska A; Kozubski W; Swatko A
Wiad Lek; 1985 Mar; 38(5):347-51. PubMed ID: 4013303
[No Abstract] [Full Text] [Related]
38. Familial metoclopramide-induced dystonic reactions.
Guala A; Mittino D; Fabbrocini P; Ghini T
Mov Disord; 1992 Oct; 7(4):385-6. PubMed ID: 1484540
[No Abstract] [Full Text] [Related]
39. Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis.
Leandro-García LJ; Leskelä S; Montero-Conde C; Landa I; López-Jimenez E; Letón R; Seeringer A; Kirchheiner J; Cascón A; Robledo M; Rodríguez-Antona C
Anal Biochem; 2009 Jun; 389(1):74-6. PubMed ID: 19303860
[TBL] [Abstract][Full Text] [Related]
40. Extrapyramidal reactions to metoclopramide and prochlorperazine.
Bateman DN; Darling WM; Boys R; Rawlins MD
Q J Med; 1989 Apr; 71(264):307-11. PubMed ID: 2594960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
